Stockreport

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma, Inc.  (INZY) 
PDF - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivota [Read more]